Can South Dako­ta's trans­genic cows help treat the flu?; A speedy re­view for Mer­ck­'s Pre­vnar ri­val in kids

4 years ago
News Briefing

Mod­er­na los­es lat­est bat­tle in key vac­cine de­liv­ery patent fight as fed­er­al ap­peal falls flat

4 years ago
Coronavirus

VBI Vac­cines ex­ecs tout ap­proval of new triple-anti­gen he­pati­tis B shot. Can they sell it?

4 years ago
R&D
FDA+

Months af­ter shock­ing in­vestors with lung can­cer win, Be­yond­Spring's lead drug hits road­block at the FDA

4 years ago
FDA+

What's fair? New ICER re­port shows pay­ers gen­er­al­ly en­sur­ing fair ac­cess to drugs

4 years ago
Pharma

Bat­tling a line­up of skep­tics, Ver­tex claims an­oth­er ear­ly clin­i­cal win — this time in kid­ney dis­ease

4 years ago
R&D

Chi­na boasts 48% price cut on in­sulin as do­mes­tic drug­mak­ers eclipse Big Phar­ma in bulk or­der

4 years ago
China
Pharma

Covid-19 roundup: Old test sam­ples sug­gest Omi­cron has been in Eu­rope for weeks; US to tight­en trav­el re­stric­tions  ...

4 years ago
Coronavirus

'Don't freak out': Ugur Sahin takes a dif­fer­ent tone on Omi­cron than his mR­NA coun­ter­part — re­ports

4 years ago
Coronavirus

Look­ing to run with Big Phar­ma, a ra­dio­phar­ma start­up with back­ing from At­las, RA thinks it has the chops to com­pete

4 years ago
Financing
Startups

Sanofi snaps up new vac­cine can­di­date and de­vis­es mR­NA game plan around it — but not for what you think

4 years ago
Deals
Cell/Gene Tx

Apol­lo Health Ven­tures pumps an­oth­er $180M in­to the bur­geon­ing race to slow ag­ing

4 years ago
Financing

FDA ad­comm nar­row­ly votes in fa­vor of Mer­ck­'s an­tivi­ral for out­pa­tient Covid-19

4 years ago
FDA+
Coronavirus

Ap­peals court puts the fi­nal nail in the cof­fin for Tec­fidera patent, adding to Bio­gen's bur­geon­ing set­backs

4 years ago
Pharma

Drug de­vel­op­ment 101: Gilead goes back to school with new pro­gram to at­tract Black and His­pan­ic stu­dents to phar­ma

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Ab­b­Vie’s Hu­mi­ra TV turns fo­cus to HS skin con­di­tion; Sanofi amps par­ent­ing pol­i­cy

4 years ago
Pharma
Marketing

Sci­wind gets li­cens­ing deal with Sanofi for meta­bol­ic dis­ease can­di­dates; Im­mu­ni­ty­Bio and En­Gene­IC reach deal for ...

4 years ago
News Briefing

As lead drug runs in­to a wall, De­ci­phera slims down its pipeline, puts 140 jobs on the chop­ping block

4 years ago
People
R&D

FDA can­cels ODAC meet­ing this week as Se­cu­ra Bio pulls ac­cel­er­at­ed ap­proval

4 years ago
FDA+

Im­muno­Gen touts a PhI­II come­back in ovar­i­an can­cer, eye­ing a 2022 ac­cel­er­at­ed ap­proval

4 years ago
R&D
FDA+

FDA rais­es con­cerns over TG Ther­a­peu­tic­s' sur­vival da­ta, plans to con­vene ODAC

4 years ago
FDA+

Start­ing from scratch: Vi­a­tris’ new brand, cul­ture set­tle in 1 year af­ter My­lan, Up­john merg­er

4 years ago
Pharma
Marketing

As­traZeneca turns down the TV vol­ume to dri­ve up at­ten­tion with Fasen­ra asth­ma cam­paign

4 years ago
Pharma
Marketing

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

4 years ago
People
First page Previous page 616617618619620621622 Next page Last page
A service from the Financial Times